Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 02:47 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

The Differential Effects of Diabetes Therapy on Inflammation

ClinicalTrials.gov · NCT02150707 · Registry updated: 2016-05-18

Condition / research focus: Diabetic Nephropathy; Type 2 Diabetes
Sponsor: University College Dublin
Countries with listed sites: Ireland
Registry dates and results: Start: 2014-05. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dipeptidyl-Peptidase IV Inhibitors (drug) — also listed as: DPP4 inhibitors
Glucagon-Like Peptide 1 (drug) — also listed as: Liraglutide, Exenatide

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Mater Misericordiae University Hospital
Dublin, Ireland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Exenatide on Liver and Heart Fat and Inflammation

ClinicalTrials.gov · NCT01951651 · Registry updated: 2016-05-16

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2010-04. Completion: 2013-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Glipizide (drug) — also listed as: Glucotrol

Where the study takes place — 1 listed sites

Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Incretin-based Drugs and the Risk of Heart Failure

ClinicalTrials.gov · NCT02456428 · Registry updated: 2016-04-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Countries with listed sites: Canada
Registry dates and results: Start: 2014-03. Completion: 2015-05 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DPP-4 inhibitors (drug) — also listed as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin
GLP-1 analogs (drug) — also listed as: incretin-based drugs, exenatide, liraglutide
Insulins (drug) — also listed as: insulins and analogues for injection, fast-acting, insulins and analogues for injection, intermediate-acting, insulins and analogues for injection, long-acting, insulins and analogues for inhalation
Biguanides (drug) — also listed as: oral hypoglycemic agent, phenformin, metformin, buformin
Sulfonylureas (drug) — also listed as: oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine
Thiazolidinediones (drug) — also listed as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
Alpha-glucosidase inhibitors (drug) — also listed as: oral hypoglycemic agent, acarbose, miglitol, voglibose
Meglitinides (drug) — also listed as: oral hypoglycemic agent, repaglinide, nateglinide

Where the study takes place — 1 listed sites

Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

ClinicalTrials.gov · NCT01432405 · Registry updated: 2016-04-12

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2007-06. Completion: 2009-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Pioglitazone (drug) — also listed as: Actos

Where the study takes place — 1 listed sites

Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

ClinicalTrials.gov · NCT02641990 · Registry updated: 2016-03-22

Condition / research focus: Healthy Adult Premenopausal Female Volunteers
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2015-12. Completion: 2016-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 20/60 mcg/day, ITCA placebo (drug)
ITCA placebo, ITCA 650 20/60 mcg/day (drug)

Where the study takes place — 2 listed sites

QPS/Miami Research Associates
Miami, Florida, United States
Site recruitment: Not reported
Compass Research
Orlando, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Incretin-based Drugs and Pancreatic Cancer

ClinicalTrials.gov · NCT02475499 · Registry updated: 2016-03-14

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Countries with listed sites: Canada
Registry dates and results: Start: 2014-03. Completion: 2015-04 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DPP-4 inhibitors (drug) — also listed as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin
GLP-1 analogs (drug) — also listed as: incretin-based drugs, exenatide, liraglutide
Sulfonylureas (drug) — also listed as: oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine
Biguanides (drug) — also listed as: oral hypoglycemic agent, phenformin, metformin, buformin
Thiazolidinediones (drug) — also listed as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
Alpha-glucosidase inhibitors (drug) — also listed as: oral hypoglycemic agent, acarbose, miglitol, voglibose
Meglitinides (drug) — also listed as: oral hypoglycemic agent, repaglinide, nateglinide

Where the study takes place — 1 listed sites

Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

ClinicalTrials.gov · NCT01373216 · Registry updated: 2016-02-02

Condition / research focus: Coronary Artery Disease; Decreased Left Ventricular Function
Sponsor: Charles University, Czech Republic
Countries with listed sites: Czechia
Registry dates and results: Start: 2011-06. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)

Where the study takes place — 1 listed sites

General University Hospital
Prague, Czechia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

ClinicalTrials.gov · NCT01744236 · Registry updated: 2015-12-09

Condition / research focus: Type 2 Diabetes
Sponsor: Amsterdam UMC, location VUmc
Countries with listed sites: Netherlands
Registry dates and results: Start: 2013-04. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Sitagliptin (drug)
Exenatide (drug)
Liraglutide placebo (drug)
Sitagliptin placebo (drug)
Exenatide placebo (drug)
L-NMMA (drug)

Where the study takes place — 1 listed sites

VU University Medical Center
Amsterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

ClinicalTrials.gov · NCT00766857 · Registry updated: 2015-12-09

Condition / research focus: Type 2 Diabetes Mellitus; Congestive Heart Failure
Sponsor: Amsterdam UMC, location VUmc
Countries with listed sites: Netherlands
Registry dates and results: Start: 2009-05. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: exenatide-Byetta
Insulin glargine (drug) — also listed as: insulin glargine-Lantus

Where the study takes place — 1 listed sites

VU University Medical Center
Amsterdam, North Holland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

ClinicalTrials.gov · NCT00803920 · Registry updated: 2015-12-03

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2006-12. Completion: 2008-02 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Impact of Food on Blood Sugar in People With Type 2 Diabetes

ClinicalTrials.gov · NCT01237314 · Registry updated: 2015-12-02

Condition / research focus: Type 2 Diabetes
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2010-11. Completion: 2013-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

ClinicalTrials.gov · NCT00806520 · Registry updated: 2015-12-02

Condition / research focus: Type 2 Diabetes
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2008-04. Completion: 2011-08 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 5 listed sites

Joslin Diabetes Center
Boston, Massachusetts, United States
Site recruitment: Not reported
International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Palm Medical Group
Las Vegas, Nevada, United States
Site recruitment: Not reported
University of North Carolina Diabetes Care Center
Durham, North Carolina, United States
Site recruitment: Not reported
Rockwood Clinic
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide

ClinicalTrials.gov · NCT00569907 · Registry updated: 2015-11-26

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2007-01. Completion: 2009-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

International Diabetes Center - Park Nicollet Health Services
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes

ClinicalTrials.gov · NCT01429506 · Registry updated: 2015-10-26

Condition / research focus: Diabetes Mellitus; Obesity
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Countries with listed sites: India
Registry dates and results: Start: 2011-01. Completion: 2012-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sleeve gastrectomy (procedure) — also listed as: Bariatric surgery, Laparoscopic sleeve gastrectomy
Intensive medical management (drug)

Where the study takes place — 1 listed sites

PGIMER
Chandigarh, Chandigarh, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

ClinicalTrials.gov · NCT02584075 · Registry updated: 2015-10-22

Condition / research focus: Coronary Endothelial Function
Sponsor: Beijing Chao Yang Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-11. Completion: 2018-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta (Exenatide) (drug)
Glucophage ( Metformin Hydrochloride) (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

ClinicalTrials.gov · NCT02584582 · Registry updated: 2015-10-22

Condition / research focus: Type 1 Diabetes
Sponsor: Hvidovre University Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-07. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Exenatide (drug)
Liquid meal test (procedure)
No drug (Baseline day) (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

ClinicalTrials.gov · NCT02560376 · Registry updated: 2015-09-25

Condition / research focus: Insulinoma; Nesidioblastosis
Sponsor: Peking Union Medical College Hospital
Countries with listed sites: China
Registry dates and results: Start: 2014-02. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-NOTA-exendin-4 (drug) — also listed as: 68Ga-NOTA-MAL-cys40-exendin-4

Where the study takes place — 1 listed sites

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

ClinicalTrials.gov · NCT00894322 · Registry updated: 2015-09-18

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2009-04. Completion: 2009-08 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide once weekly (drug)
exenatide once weekly (drug)
Placebo (other)

Where the study takes place — 1 listed sites

Research Site
Lincoln, Nebraska, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT00359762 · Registry updated: 2015-09-15

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: Austria · Czechia · Finland · France · Germany · Hungary · Ireland · Israel · Italy · Mexico · Poland · Spain · Switzerland · United Kingdom
Registry dates and results: Start: 2006-09. Completion: 2011-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
glimepiride (drug) — also listed as: Amaryl

Where the study takes place — 114 listed sites

Research Site
Graz, Austria
Site recruitment: Not reported
Research Site
Innsbruck, Austria
Site recruitment: Not reported
Research Site
Salzburg, Austria
Site recruitment: Not reported
Research Site
Vienna, Austria
Site recruitment: Not reported
Research Site
Beroun, Czechia
Site recruitment: Not reported
Research Site
České Budějovice, Czechia
Site recruitment: Not reported
Research Site
Hradec Králové, Czechia
Site recruitment: Not reported
Research Site
Liberec, Czechia
Site recruitment: Not reported
Research Site
Písek, Czechia
Site recruitment: Not reported
Research Site
Prague, Czechia
Site recruitment: Not reported
Research Site
Třebíč, Czechia
Site recruitment: Not reported
Research Site
Helsinki, Finland
Site recruitment: Not reported
Research Site
Kuopio, Finland
Site recruitment: Not reported
Research Site
Pori, Finland
Site recruitment: Not reported
Research Site
Vaasa, Finland
Site recruitment: Not reported
Research Site
Alençon, France
Site recruitment: Not reported
Research Site
Bois-Guillaume, France
Site recruitment: Not reported
Research Site
Bourg-des-Comptes, France
Site recruitment: Not reported
Research Site
Broglie, France
Site recruitment: Not reported
Research Site
Bron, France
Site recruitment: Not reported
Research Site
Fléville-devant-Nancy, France
Site recruitment: Not reported
Research Site
Le Creusot, France
Site recruitment: Not reported
Research Site
Le Mans, France
Site recruitment: Not reported
Research Site
Loudun, France
Site recruitment: Not reported
Research Site
Montigny-lès-Metz, France
Site recruitment: Not reported
Research Site
Nevers, France
Site recruitment: Not reported
Research Site
Strasbourg, France
Site recruitment: Not reported
Research Site
Thouars, France
Site recruitment: Not reported
Research Site
Tours, France
Site recruitment: Not reported
Research Site
Valréas, France
Site recruitment: Not reported
Research Site
Vénissieux, France
Site recruitment: Not reported
Research Site
Vihiers, France
Site recruitment: Not reported
Research Site
Altona, Germany
Site recruitment: Not reported
Research Site
Aschaffenburg, Germany
Site recruitment: Not reported
Research Site
Bad Staffelstein, Germany
Site recruitment: Not reported
Research Site
Dresden, Germany
Site recruitment: Not reported
Research Site
Eisenach, Germany
Site recruitment: Not reported
Research Site
Essen, Germany
Site recruitment: Not reported
Research Site
Essen Schonnebeck, Germany
Site recruitment: Not reported
Research Site
Falkensee, Germany
Site recruitment: Not reported
Research Site
Fulda, Germany
Site recruitment: Not reported
Research Site
Hamburg, Germany
Site recruitment: Not reported
Research Site
Hamburg-Ottmarschen, Germany
Site recruitment: Not reported
Research Site
Heidelberg, Germany
Site recruitment: Not reported
Research Site
Leipzig, Germany
Site recruitment: Not reported
Research Site
Münster, Germany
Site recruitment: Not reported
Research Site
Saarbrücken, Germany
Site recruitment: Not reported
Research Site
Saint Ingbert, Germany
Site recruitment: Not reported
Research Site
Schenklengsfeld, Germany
Site recruitment: Not reported
Research Site
Schkeuditz, Germany
Site recruitment: Not reported
Research Site
Witten, Germany
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Gyula, Hungary
Site recruitment: Not reported
Research Site
Kecskemét, Hungary
Site recruitment: Not reported
Research Site
Veszprém, Hungary
Site recruitment: Not reported
Research Site
Zalaegerszeg, Hungary
Site recruitment: Not reported
Research Site
County Galway, Ireland
Site recruitment: Not reported
Research Site
County Waterford, Ireland
Site recruitment: Not reported
Research Site
Dublin, Ireland
Site recruitment: Not reported
Research Site
Haifa, Israel
Site recruitment: Not reported
Research Site
Holon, Israel
Site recruitment: Not reported
Research Site
Jerusalem, Israel
Site recruitment: Not reported
Research Site
Tel Litwinsky, Israel
Site recruitment: Not reported
Research Site
Ancona, Italy
Site recruitment: Not reported
Research Site
Arenzano, Italy
Site recruitment: Not reported
Research Site
Atri, Italy
Site recruitment: Not reported
Research Site
Bergamo, Italy
Site recruitment: Not reported
Research Site
Catanzaro, Italy
Site recruitment: Not reported
Research Site
Florence, Italy
Site recruitment: Not reported
Research Site
Foggia, Italy
Site recruitment: Not reported
Research Site
Forlì, Italy
Site recruitment: Not reported
Research Site
Genova, Italy
Site recruitment: Not reported
Research Site
Grosseto, Italy
Site recruitment: Not reported
Research Site
Milan, Italy
Site recruitment: Not reported
Research Site
Monserrato (Cagliari), Italy
Site recruitment: Not reported
Research Site
Naples, Italy
Site recruitment: Not reported
Research Site
Palermo, Italy
Site recruitment: Not reported
Research Site
Perugia, Italy
Site recruitment: Not reported
Research Site
Pescara, Italy
Site recruitment: Not reported
Research Site
Pisa, Italy
Site recruitment: Not reported
Research Site
Ravenna, Italy
Site recruitment: Not reported
Research Site
Roma, Italy
Site recruitment: Not reported
Research Site
San Benedetto del Tronto, Italy
Site recruitment: Not reported
Research Site
Siena, Italy
Site recruitment: Not reported
Research Site
Treviso, Italy
Site recruitment: Not reported
Research Site
Verona, Italy
Site recruitment: Not reported
Research Site
Celaya, Guanajuato, Mexico
Site recruitment: Not reported
Research Site
Pachuca, Hidalgo, Mexico
Site recruitment: Not reported
Research Site
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Research Site
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Research Site
Bialystok, Poland
Site recruitment: Not reported
Research Site
Bydgoszcz, Poland
Site recruitment: Not reported
Research Site
Lublin, Poland
Site recruitment: Not reported
Research Site
Szczecin, Poland
Site recruitment: Not reported
Research Site
Warsaw, Poland
Site recruitment: Not reported
Research Site
Wroclaw, Poland
Site recruitment: Not reported
Research Site
Barcelona, Spain
Site recruitment: Not reported
Research Site
Madrid, Spain
Site recruitment: Not reported
Research Site
Fribourg, Switzerland
Site recruitment: Not reported
Research Site
Geneva, Switzerland
Site recruitment: Not reported
Research Site
Lausanne, Switzerland
Site recruitment: Not reported
Research Site
Lucerne, Switzerland
Site recruitment: Not reported
Research Site
Bath, United Kingdom
Site recruitment: Not reported
Research Site
Belfast, United Kingdom
Site recruitment: Not reported
Research Site
Brandford on Avon, United Kingdom
Site recruitment: Not reported
Research Site
County Antrim, United Kingdom
Site recruitment: Not reported
Research Site
Downpatrick, United Kingdom
Site recruitment: Not reported
Research Site
Frome, United Kingdom
Site recruitment: Not reported
Research Site
Midsomer Norton, United Kingdom
Site recruitment: Not reported
Research Site
Omagh, United Kingdom
Site recruitment: Not reported
Research Site
Penzance, United Kingdom
Site recruitment: Not reported
Research Site
Plymouth, United Kingdom
Site recruitment: Not reported
Research Site
Southdown, United Kingdom
Site recruitment: Not reported
Research Site
Wiltshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00477581 · Registry updated: 2015-08-26

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2007-05. Completion: 2007-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
sitagliptin (drug) — also listed as: Januvia

Where the study takes place — 19 listed sites

Research Site
Los Angeles, California, United States
Site recruitment: Not reported
Research Site
Spring Valley, California, United States
Site recruitment: Not reported
Research Site
Miami, Florida, United States
Site recruitment: Not reported
Research Site
Pembroke Pines, Florida, United States
Site recruitment: Not reported
Research Site
Chicago, Illinois, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Detroit, Michigan, United States
Site recruitment: Not reported
Research Site
Butte, Montana, United States
Site recruitment: Not reported
Research Site
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
Research Site
Cincinnati, Ohio, United States
Site recruitment: Not reported
Research Site
Marion, Ohio, United States
Site recruitment: Not reported
Research Site
Eugene, Oregon, United States
Site recruitment: Not reported
Research Site
Portland, Oregon, United States
Site recruitment: Not reported
Research Site
Charleston, South Carolina, United States
Site recruitment: Not reported
Research Site
Greer, South Carolina, United States
Site recruitment: Not reported
Research Site
Austin, Texas, United States
Site recruitment: Not reported
Research Site
Corpus Christi, Texas, United States
Site recruitment: Not reported
Research Site
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-08 02:47 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

The Differential Effects of Diabetes Therapy on Inflammation

ClinicalTrials.gov · NCT02150707 · Registry updated: 2016-05-18

Condition / research focus: Diabetic Nephropathy; Type 2 Diabetes
Sponsor: University College Dublin
Countries with listed sites: Ireland
Registry dates and results: Start: 2014-05. Completion: 2015-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dipeptidyl-Peptidase IV Inhibitors (drug) — also listed as: DPP4 inhibitors
Glucagon-Like Peptide 1 (drug) — also listed as: Liraglutide, Exenatide

Where the study takes place — 1 listed sites

Mater Misericordiae University Hospital
Dublin, Ireland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Exenatide on Liver and Heart Fat and Inflammation

ClinicalTrials.gov · NCT01951651 · Registry updated: 2016-05-16

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2010-04. Completion: 2013-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Glipizide (drug) — also listed as: Glucotrol

Where the study takes place — 1 listed sites

Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Incretin-based Drugs and the Risk of Heart Failure

ClinicalTrials.gov · NCT02456428 · Registry updated: 2016-04-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Countries with listed sites: Canada
Registry dates and results: Start: 2014-03. Completion: 2015-05 (may be estimated). No results posted in this registry response.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DPP-4 inhibitors (drug) — also listed as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin
GLP-1 analogs (drug) — also listed as: incretin-based drugs, exenatide, liraglutide
Insulins (drug) — also listed as: insulins and analogues for injection, fast-acting, insulins and analogues for injection, intermediate-acting, insulins and analogues for injection, long-acting, insulins and analogues for inhalation
Biguanides (drug) — also listed as: oral hypoglycemic agent, phenformin, metformin, buformin
Sulfonylureas (drug) — also listed as: oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine
Thiazolidinediones (drug) — also listed as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
Alpha-glucosidase inhibitors (drug) — also listed as: oral hypoglycemic agent, acarbose, miglitol, voglibose
Meglitinides (drug) — also listed as: oral hypoglycemic agent, repaglinide, nateglinide

Where the study takes place — 1 listed sites

Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

ClinicalTrials.gov · NCT01432405 · Registry updated: 2016-04-12

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2007-06. Completion: 2009-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug) — also listed as: Byetta
Pioglitazone (drug) — also listed as: Actos

Where the study takes place — 1 listed sites

Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

ClinicalTrials.gov · NCT02641990 · Registry updated: 2016-03-22

Condition / research focus: Healthy Adult Premenopausal Female Volunteers
Sponsor: Intarcia Therapeutics
Countries with listed sites: United States
Registry dates and results: Start: 2015-12. Completion: 2016-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ITCA 650 20/60 mcg/day, ITCA placebo (drug)
ITCA placebo, ITCA 650 20/60 mcg/day (drug)

Where the study takes place — 2 listed sites

QPS/Miami Research Associates
Miami, Florida, United States
Site recruitment: Not reported
Compass Research
Orlando, Florida, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Incretin-based Drugs and Pancreatic Cancer

ClinicalTrials.gov · NCT02475499 · Registry updated: 2016-03-14

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Countries with listed sites: Canada
Registry dates and results: Start: 2014-03. Completion: 2015-04 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DPP-4 inhibitors (drug) — also listed as: incretin-based drugs, sitagliptin, vildagliptin, saxagliptin
GLP-1 analogs (drug) — also listed as: incretin-based drugs, exenatide, liraglutide
Sulfonylureas (drug) — also listed as: oral hypoglycemic agent, glibenclamide, chlorpropamide, tolbutamide, glibornuride, tolazamide, carbutamide, glipizide, gliquidone, gliclazide, metahexamide, glisoxepide, glimepiride, acetohexamide, glymidine
Biguanides (drug) — also listed as: oral hypoglycemic agent, phenformin, metformin, buformin
Thiazolidinediones (drug) — also listed as: oral hypoglycemic agent, troglitazone, rosiglitazone, pioglitazone
Alpha-glucosidase inhibitors (drug) — also listed as: oral hypoglycemic agent, acarbose, miglitol, voglibose
Meglitinides (drug) — also listed as: oral hypoglycemic agent, repaglinide, nateglinide

Where the study takes place — 1 listed sites

Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

ClinicalTrials.gov · NCT01373216 · Registry updated: 2016-02-02

Condition / research focus: Coronary Artery Disease; Decreased Left Ventricular Function
Sponsor: Charles University, Czech Republic
Countries with listed sites: Czechia
Registry dates and results: Start: 2011-06. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide (drug)

Where the study takes place — 1 listed sites

General University Hospital
Prague, Czechia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

ClinicalTrials.gov · NCT01744236 · Registry updated: 2015-12-09

Condition / research focus: Type 2 Diabetes
Sponsor: Amsterdam UMC, location VUmc
Countries with listed sites: Netherlands
Registry dates and results: Start: 2013-04. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Sitagliptin (drug)
Exenatide (drug)
Liraglutide placebo (drug)
Sitagliptin placebo (drug)
Exenatide placebo (drug)
L-NMMA (drug)

Where the study takes place — 1 listed sites

VU University Medical Center
Amsterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

ClinicalTrials.gov · NCT00766857 · Registry updated: 2015-12-09

Condition / research focus: Type 2 Diabetes Mellitus; Congestive Heart Failure
Sponsor: Amsterdam UMC, location VUmc
Countries with listed sites: Netherlands
Registry dates and results: Start: 2009-05. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: exenatide-Byetta
Insulin glargine (drug) — also listed as: insulin glargine-Lantus

Where the study takes place — 1 listed sites

VU University Medical Center
Amsterdam, North Holland, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

ClinicalTrials.gov · NCT00803920 · Registry updated: 2015-12-03

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2006-12. Completion: 2008-02 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Impact of Food on Blood Sugar in People With Type 2 Diabetes

ClinicalTrials.gov · NCT01237314 · Registry updated: 2015-12-02

Condition / research focus: Type 2 Diabetes
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2010-11. Completion: 2013-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

ClinicalTrials.gov · NCT00806520 · Registry updated: 2015-12-02

Condition / research focus: Type 2 Diabetes
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2008-04. Completion: 2011-08 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 5 listed sites

Joslin Diabetes Center
Boston, Massachusetts, United States
Site recruitment: Not reported
International Diabetes Center
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Palm Medical Group
Las Vegas, Nevada, United States
Site recruitment: Not reported
University of North Carolina Diabetes Care Center
Durham, North Carolina, United States
Site recruitment: Not reported
Rockwood Clinic
Spokane, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide

ClinicalTrials.gov · NCT00569907 · Registry updated: 2015-11-26

Condition / research focus: Diabetes Mellitus Type 2
Sponsor: HealthPartners Institute
Countries with listed sites: United States
Registry dates and results: Start: 2007-01. Completion: 2009-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

International Diabetes Center - Park Nicollet Health Services
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes

ClinicalTrials.gov · NCT01429506 · Registry updated: 2015-10-26

Condition / research focus: Diabetes Mellitus; Obesity
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
Countries with listed sites: India
Registry dates and results: Start: 2011-01. Completion: 2012-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sleeve gastrectomy (procedure) — also listed as: Bariatric surgery, Laparoscopic sleeve gastrectomy
Intensive medical management (drug)

Where the study takes place — 1 listed sites

PGIMER
Chandigarh, Chandigarh, India
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

ClinicalTrials.gov · NCT02584075 · Registry updated: 2015-10-22

Condition / research focus: Coronary Endothelial Function
Sponsor: Beijing Chao Yang Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-11. Completion: 2018-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta (Exenatide) (drug)
Glucophage ( Metformin Hydrochloride) (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

ClinicalTrials.gov · NCT02584582 · Registry updated: 2015-10-22

Condition / research focus: Type 1 Diabetes
Sponsor: Hvidovre University Hospital
Countries with listed sites: No country reported
Registry dates and results: Start: 2015-07. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Exenatide (drug)
Liquid meal test (procedure)
No drug (Baseline day) (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Early Phase 1UnknownINTERVENTIONAL

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

ClinicalTrials.gov · NCT02560376 · Registry updated: 2015-09-25

Condition / research focus: Insulinoma; Nesidioblastosis
Sponsor: Peking Union Medical College Hospital
Countries with listed sites: China
Registry dates and results: Start: 2014-02. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-NOTA-exendin-4 (drug) — also listed as: 68Ga-NOTA-MAL-cys40-exendin-4

Where the study takes place — 1 listed sites

Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

ClinicalTrials.gov · NCT00894322 · Registry updated: 2015-09-18

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2009-04. Completion: 2009-08 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide once weekly (drug)
exenatide once weekly (drug)
Placebo (other)

Where the study takes place — 1 listed sites

Research Site
Lincoln, Nebraska, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT00359762 · Registry updated: 2015-09-15

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: Austria · Czechia · Finland · France · Germany · Hungary · Ireland · Israel · Italy · Mexico · Poland · Spain · Switzerland · United Kingdom
Registry dates and results: Start: 2006-09. Completion: 2011-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
glimepiride (drug) — also listed as: Amaryl

Where the study takes place — 114 listed sites

Research Site
Graz, Austria
Site recruitment: Not reported
Research Site
Innsbruck, Austria
Site recruitment: Not reported
Research Site
Salzburg, Austria
Site recruitment: Not reported
Research Site
Vienna, Austria
Site recruitment: Not reported
Research Site
Beroun, Czechia
Site recruitment: Not reported
Research Site
České Budějovice, Czechia
Site recruitment: Not reported
Research Site
Hradec Králové, Czechia
Site recruitment: Not reported
Research Site
Liberec, Czechia
Site recruitment: Not reported
Research Site
Písek, Czechia
Site recruitment: Not reported
Research Site
Prague, Czechia
Site recruitment: Not reported
Research Site
Třebíč, Czechia
Site recruitment: Not reported
Research Site
Helsinki, Finland
Site recruitment: Not reported
Research Site
Kuopio, Finland
Site recruitment: Not reported
Research Site
Pori, Finland
Site recruitment: Not reported
Research Site
Vaasa, Finland
Site recruitment: Not reported
Research Site
Alençon, France
Site recruitment: Not reported
Research Site
Bois-Guillaume, France
Site recruitment: Not reported
Research Site
Bourg-des-Comptes, France
Site recruitment: Not reported
Research Site
Broglie, France
Site recruitment: Not reported
Research Site
Bron, France
Site recruitment: Not reported
Research Site
Fléville-devant-Nancy, France
Site recruitment: Not reported
Research Site
Le Creusot, France
Site recruitment: Not reported
Research Site
Le Mans, France
Site recruitment: Not reported
Research Site
Loudun, France
Site recruitment: Not reported
Research Site
Montigny-lès-Metz, France
Site recruitment: Not reported
Research Site
Nevers, France
Site recruitment: Not reported
Research Site
Strasbourg, France
Site recruitment: Not reported
Research Site
Thouars, France
Site recruitment: Not reported
Research Site
Tours, France
Site recruitment: Not reported
Research Site
Valréas, France
Site recruitment: Not reported
Research Site
Vénissieux, France
Site recruitment: Not reported
Research Site
Vihiers, France
Site recruitment: Not reported
Research Site
Altona, Germany
Site recruitment: Not reported
Research Site
Aschaffenburg, Germany
Site recruitment: Not reported
Research Site
Bad Staffelstein, Germany
Site recruitment: Not reported
Research Site
Dresden, Germany
Site recruitment: Not reported
Research Site
Eisenach, Germany
Site recruitment: Not reported
Research Site
Essen, Germany
Site recruitment: Not reported
Research Site
Essen Schonnebeck, Germany
Site recruitment: Not reported
Research Site
Falkensee, Germany
Site recruitment: Not reported
Research Site
Fulda, Germany
Site recruitment: Not reported
Research Site
Hamburg, Germany
Site recruitment: Not reported
Research Site
Hamburg-Ottmarschen, Germany
Site recruitment: Not reported
Research Site
Heidelberg, Germany
Site recruitment: Not reported
Research Site
Leipzig, Germany
Site recruitment: Not reported
Research Site
Münster, Germany
Site recruitment: Not reported
Research Site
Saarbrücken, Germany
Site recruitment: Not reported
Research Site
Saint Ingbert, Germany
Site recruitment: Not reported
Research Site
Schenklengsfeld, Germany
Site recruitment: Not reported
Research Site
Schkeuditz, Germany
Site recruitment: Not reported
Research Site
Witten, Germany
Site recruitment: Not reported
Research Site
Budapest, Hungary
Site recruitment: Not reported
Research Site
Gyula, Hungary
Site recruitment: Not reported
Research Site
Kecskemét, Hungary
Site recruitment: Not reported
Research Site
Veszprém, Hungary
Site recruitment: Not reported
Research Site
Zalaegerszeg, Hungary
Site recruitment: Not reported
Research Site
County Galway, Ireland
Site recruitment: Not reported
Research Site
County Waterford, Ireland
Site recruitment: Not reported
Research Site
Dublin, Ireland
Site recruitment: Not reported
Research Site
Haifa, Israel
Site recruitment: Not reported
Research Site
Holon, Israel
Site recruitment: Not reported
Research Site
Jerusalem, Israel
Site recruitment: Not reported
Research Site
Tel Litwinsky, Israel
Site recruitment: Not reported
Research Site
Ancona, Italy
Site recruitment: Not reported
Research Site
Arenzano, Italy
Site recruitment: Not reported
Research Site
Atri, Italy
Site recruitment: Not reported
Research Site
Bergamo, Italy
Site recruitment: Not reported
Research Site
Catanzaro, Italy
Site recruitment: Not reported
Research Site
Florence, Italy
Site recruitment: Not reported
Research Site
Foggia, Italy
Site recruitment: Not reported
Research Site
Forlì, Italy
Site recruitment: Not reported
Research Site
Genova, Italy
Site recruitment: Not reported
Research Site
Grosseto, Italy
Site recruitment: Not reported
Research Site
Milan, Italy
Site recruitment: Not reported
Research Site
Monserrato (Cagliari), Italy
Site recruitment: Not reported
Research Site
Naples, Italy
Site recruitment: Not reported
Research Site
Palermo, Italy
Site recruitment: Not reported
Research Site
Perugia, Italy
Site recruitment: Not reported
Research Site
Pescara, Italy
Site recruitment: Not reported
Research Site
Pisa, Italy
Site recruitment: Not reported
Research Site
Ravenna, Italy
Site recruitment: Not reported
Research Site
Roma, Italy
Site recruitment: Not reported
Research Site
San Benedetto del Tronto, Italy
Site recruitment: Not reported
Research Site
Siena, Italy
Site recruitment: Not reported
Research Site
Treviso, Italy
Site recruitment: Not reported
Research Site
Verona, Italy
Site recruitment: Not reported
Research Site
Celaya, Guanajuato, Mexico
Site recruitment: Not reported
Research Site
Pachuca, Hidalgo, Mexico
Site recruitment: Not reported
Research Site
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Research Site
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Research Site
Bialystok, Poland
Site recruitment: Not reported
Research Site
Bydgoszcz, Poland
Site recruitment: Not reported
Research Site
Lublin, Poland
Site recruitment: Not reported
Research Site
Szczecin, Poland
Site recruitment: Not reported
Research Site
Warsaw, Poland
Site recruitment: Not reported
Research Site
Wroclaw, Poland
Site recruitment: Not reported
Research Site
Barcelona, Spain
Site recruitment: Not reported
Research Site
Madrid, Spain
Site recruitment: Not reported
Research Site
Fribourg, Switzerland
Site recruitment: Not reported
Research Site
Geneva, Switzerland
Site recruitment: Not reported
Research Site
Lausanne, Switzerland
Site recruitment: Not reported
Research Site
Lucerne, Switzerland
Site recruitment: Not reported
Research Site
Bath, United Kingdom
Site recruitment: Not reported
Research Site
Belfast, United Kingdom
Site recruitment: Not reported
Research Site
Brandford on Avon, United Kingdom
Site recruitment: Not reported
Research Site
County Antrim, United Kingdom
Site recruitment: Not reported
Research Site
Downpatrick, United Kingdom
Site recruitment: Not reported
Research Site
Frome, United Kingdom
Site recruitment: Not reported
Research Site
Midsomer Norton, United Kingdom
Site recruitment: Not reported
Research Site
Omagh, United Kingdom
Site recruitment: Not reported
Research Site
Penzance, United Kingdom
Site recruitment: Not reported
Research Site
Plymouth, United Kingdom
Site recruitment: Not reported
Research Site
Southdown, United Kingdom
Site recruitment: Not reported
Research Site
Wiltshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00477581 · Registry updated: 2015-08-26

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2007-05. Completion: 2007-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

exenatide (drug) — also listed as: Byetta
sitagliptin (drug) — also listed as: Januvia

Where the study takes place — 19 listed sites

Research Site
Los Angeles, California, United States
Site recruitment: Not reported
Research Site
Spring Valley, California, United States
Site recruitment: Not reported
Research Site
Miami, Florida, United States
Site recruitment: Not reported
Research Site
Pembroke Pines, Florida, United States
Site recruitment: Not reported
Research Site
Chicago, Illinois, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Indianapolis, Indiana, United States
Site recruitment: Not reported
Research Site
Detroit, Michigan, United States
Site recruitment: Not reported
Research Site
Butte, Montana, United States
Site recruitment: Not reported
Research Site
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
Research Site
Cincinnati, Ohio, United States
Site recruitment: Not reported
Research Site
Marion, Ohio, United States
Site recruitment: Not reported
Research Site
Eugene, Oregon, United States
Site recruitment: Not reported
Research Site
Portland, Oregon, United States
Site recruitment: Not reported
Research Site
Charleston, South Carolina, United States
Site recruitment: Not reported
Research Site
Greer, South Carolina, United States
Site recruitment: Not reported
Research Site
Austin, Texas, United States
Site recruitment: Not reported
Research Site
Corpus Christi, Texas, United States
Site recruitment: Not reported
Research Site
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →